Literature DB >> 19483735

Medical oncology: Endocrine-therapy-related symptoms and breast cancer.

Aman U Buzdar1.   

Abstract

The association of a treatment-related adverse effect with treatment success has been reported in various clinical situations. The development of vasomotor or joint symptoms is an indication of therapeutic benefit in women receiving endocrine treatment for hormone-receptor-positive breast cancer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19483735     DOI： 10.1038/nrclinonc.2009.67

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

Authors:  William F Anderson; Nilanjan Chatterjee; William B Ershler; Otis W Brawley
Journal:  Breast Cancer Res Treat       Date:  2002-11       Impact factor: 4.872

2.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

Authors:  A Buzdar; A Howell; J Cuzick; C Wale; W Distler; G Hoctin-Boes; J Houghton; G Y Locker; J M Nabholtz
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

Review 3.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Authors:  Román Peréz-Soler; Leonard Saltz
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

4.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

5.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

7.  Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.

Authors:  Aman U Buzdar; R Charles Coombes; Paul E Goss; Eric P Winer
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

8.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

9.  Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; David Cella; Lesley Fallowfield
Journal:  Lancet Oncol       Date:  2008-10-29       Impact factor: 41.316

Review 10.  Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Authors:  Søren Lykke Petersen
Journal:  Dan Med Bull       Date:  2007-05
  10 in total
  1 in total

1.  The "Sharp" blade against HIF-mediated metastasis.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.